Jan Skvarka - 11 May 2021 Form 4 Insider Report for Trillium Therapeutics Inc.

Role: President and CEO, Director
Signature: /s/ James Parsons, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 11 May 2021
Net transactions value: -$1,149,139
Form type: 4
Filing time: 13 May 2021, 16:12:45 UTC
Next filing: 19 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRIL	Common Shares	Options Exercise	$39,042	+87,500		$0.4462^*	87,500	11 May 2021	Direct	F1
transaction	TRIL	Common Shares	Options Exercise	$6,028	+19,198	+22%	$0.3140^*	106,698	11 May 2021	Direct	F2
transaction	TRIL	Common Shares	Sale	$981,803	-106,698	-100%	$9.20^*	0	11 May 2021	Direct	F3
transaction	TRIL	Common Shares	Options Exercise	$7,474	+23,802		$0.3140^*	23,802	12 May 2021	Direct	F2
transaction	TRIL	Common Shares	Sale	$219,880	-23,802	-100%	$9.24^*	0	12 May 2021	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRIL	Stock Option (Right to Buy)	Options Exercise	$0	-87,500	-7%	$0.000000	1,162,500	11 May 2021	Common Shares	87,500	$0.4462	Direct	F1, F5
transaction	TRIL	Stock Option (Right to Buy)	Options Exercise	$0	-19,198	-8%	$0.000000	220,802	11 May 2021	Common Shares	19,198	$0.3140	Direct	F2, F5
transaction	TRIL	Stock Option (Right to Buy)	Options Exercise	$0	-23,802	-11%	$0.000000	197,000	12 May 2021	Common Shares	23,802	$0.3140	Direct	F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD.
F2	The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD.
F3	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.36 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.